Early response to idursulfase treatment in a 3 year-old boy affected of Hunter syndrome

European Journal of Medical Genetics

Volumn 51, Issue 3, 2008, Pages 268-271

  Galán Gómez, Enrique ^a   Guerrero Rico, Ana ^a   Cáceres Marzal, Cristina ^a   Zambrano Castaño, Moises ^a   Moreno Tejero, María Luisa ^a   Grande Tejada, Ana María ^a   Fernández Hernández, Santiago ^a   Vaquerizo Madrid, Julián ^a   Cardesa García, Juan J ^a  

^a HOSPITAL INFANTA CRISTINA   (Spain)

Author keywords

Early treatment; Hunter syndrome; Idursulfatase

Indexed keywords

CREATININE; GLYCOSAMINOGLYCAN; IDURONATE 2 SULFATASE;

BRAIN MALFORMATION; CASE REPORT; ENZYME ACTIVITY; ENZYME REPLACEMENT; EXON; GENE MUTATION; HEPATOMEGALY; HUMAN; HUNTER SYNDROME; HYPOSPADIAS; LETTER; LIVER WEIGHT; MALE; MITRAL VALVE REGURGITATION; PHYSICAL ACTIVITY; PRESCHOOL CHILD; SPLENOMEGALY;

CHILD, PRESCHOOL; HUMANS; IDURONATE SULFATASE; MALE; MUCOPOLYSACCHARIDOSIS II;

EID: 43049175045     PISSN: 17697212     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejmg.2008.02.005     Document Type: Letter

References (9)

1. Neufeld E.F., and Muenzer J. The mucopolysaccharidoses. In: Scriver C.R. (Ed). The Metabolic and Molecular Bases of Inherited Disease (2001), McGraw-Hill, New York 3421-3452
2. Meikle P.J., Hopwood J.J., Clauge A.E., and Carey W.F. Prevalence of lysosomal storage disorders. JAMA 281 (1999) 249-254
3. Muenzer J., Wraith J.E., Beck M., Giugliani R., Harmatz P., Eng C.M., Vellodi A., Martin R., Ramaswami U., Gucsavas-Calikoglu M., et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 8 8 (2006) 465-473
4. Barton N.W., Brady R.O., Dambrosia J.M., Di Bisceglie A.M., Doppelt S.H., Hill S.C., Mankin H.J., Murria G.J., Parker R.I., Argoff C.E., et al. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerobrosidase for Gaucher's disease. New Eng J Med 324 (1991) 1464-1470
5. Schiffmann R., Kopp J.B., Austin III H.A., Sabnis S., Moore D.F., Weibel T., Balow J.E., and Brady R.O. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285 (2001) 2743-2749
6. Eng C.M., Guffon N., Wilcox W.R., Germain D.P., Lee P., Waldek S., Caplan L., Linthorst G.E., and Desnick R.J. Safety and efficacy of recombinant human alphagalactosidase A replacement in Fabry's disease. New Eng J Med 345 (2001) 9-16
7. Wraith J.E., Clarke L.A., Beck M., Kolodny E.H., Pastores G.M., Muenzaer J., Rapoport D.M., Berger K.I., Swiedler S.J., Kakkis E.D., et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo controlled, multinational study of recombinant human α-l-iduronidase (laronidase). J Pediatrics 144 (2004) 581-588
8. Kakis E.D., Muenzer J., Tiller G.E., Waber L., Belmont J., Passage M., Izykowski B., Phillips J., Doroshow R., Wallot I., Hoft R., and Neufeld E.F. Enzymereplacement therapy in mucopolysaccharidosis I. New Eng J Med 344 (2001) 182-188
9. Harmatz P., Ketteridge D., Giugliani R., Guffon N., Teles E.L., Miranda M.C., Yu Z.F., Swiedler S.J., and Hopwood J.J. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a Phase 2 open-label clinical study of recombinant human Nacetylgalactosidase-4-sulfatase. Pediatrics 115 (2005) e681-e689